Phase II Trial of Irinotecan plus Cisplatin Combination as First Line Therapy for Patients with Small cell Lung Cancer

소세포폐암 환자에서 1차 항암 치료제로서 Irinotecan 과 Cisplatin 병합요법에 관한 2상 연구

  • Jeong, Hye Cheol (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Lee, Sang Yeub (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Kim, Jung Ha (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Ha, Eun Sil (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Jung, Jin Yong (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Lee, Kyung Ju (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Lee, Seung Hyeun (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Kim, Se Joong (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Lee, Eun Joo (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Hur, Gyu Young (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Lee, Sung Yong (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Kim, Je Hyeong (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Shin, Chol (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Shim, Jae Jeong (Department of Internal Medicine, College of Medicine, Korea University) ;
  • In, Kwang Ho (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Kang, Kyung Ho (Department of Internal Medicine, College of Medicine, Korea University) ;
  • Yoo, Se Hwa (Department of Internal Medicine, College of Medicine, Korea University)
  • 정혜철 (고려대학교 내과학교실 호흡기 내과) ;
  • 이상엽 (고려대학교 내과학교실 호흡기 내과) ;
  • 김정하 (고려대학교 내과학교실 호흡기 내과) ;
  • 하은실 (고려대학교 내과학교실 호흡기 내과) ;
  • 정진용 (고려대학교 내과학교실 호흡기 내과) ;
  • 이경주 (고려대학교 내과학교실 호흡기 내과) ;
  • 이승현 (고려대학교 내과학교실 호흡기 내과) ;
  • 김세중 (고려대학교 내과학교실 호흡기 내과) ;
  • 이은주 (고려대학교 내과학교실 호흡기 내과) ;
  • 허규영 (고려대학교 내과학교실 호흡기 내과) ;
  • 이승룡 (고려대학교 내과학교실 호흡기 내과) ;
  • 김제형 (고려대학교 내과학교실 호흡기 내과) ;
  • 신철 (고려대학교 내과학교실 호흡기 내과) ;
  • 심재정 (고려대학교 내과학교실 호흡기 내과) ;
  • 인광호 (고려대학교 내과학교실 호흡기 내과) ;
  • 강경호 (고려대학교 내과학교실 호흡기 내과) ;
  • 유세화 (고려대학교 내과학교실 호흡기 내과)
  • Received : 2005.08.31
  • Accepted : 2005.12.12
  • Published : 2006.01.30

Abstract

Background : Recently, there have been several studies showing that irinotecan hydrochloride, a topoisomerase I inhibitor, is effective against extensive disease(ED) small cell lung cancer (SCLC). We conducted a phase II trial to evaluate the efficacy and toxicity of irinotecan plus cisplatin as a 1st line therapy for both limited and extensive disease SCLC. Methods : The study was conducted between January 2002 and June 2004. Patients were treated with $60mg/m^2$ irinotecan on day 1, 8, 15 and $60mg/m^2$ cisplatin on day 1, every 4 weeks. During concurrent thoracic irradiation for limited disease (LD)-SCLC patients, dose of irinotecan was reduced to $40mg/m^2$. Prophylactic cranial irradiation was given to patients with complete remission (CR) after chemotherapy. Results : Median ages of LD- and ED- SCLC were 64 years and performance status (PS) was 0-2. In patients with LD-SCLC, the response rate after concurrent chemoradiotherapy was 85% (CR, 6; Partial response [PR], 11). The median survival was 20 months (95% CIs, 15.6 to 24.4) with 1-and 2-year survival rates of 85% and 35%, respectively. Median progression free survival (PFS) was 12 months (95% CIs, 6.2 to 18.1) with 1- year PFS of 36%. In ED-SCLC, the response rate was 83.4% (CR, 1; PR, 14). The median survival was 14.5 months (95% CIs, 8.8 to 20.1) with 1-year survival rates of 75%. Median PFS was 6.3 months (95% CIs, 5.6 to 7.1) with 1- year PFS of 20%. The major toxicities (grade 3 or 4) of this regimen included leukopenia, anemia, thrombocytopenia, nausea/vomiting, and diarrhea without life threatening complication. Conclusion : Our data shows that the combination of irinotecan plus cisplatin as a first line therapy is effective and tolerable in the treatment of both LD- and ED- SCLC.

연구배경 : 확장성 병기 소세포폐암에서 irinotecan 과 cisplatin 을 사용시 etoposide 와 cisplatin 에 비해 효과적이라는 것이 밝혀 졌다. 그러나 제한성 병기 소세포폐암에서의 연구는 매우 제한적이다. 따라서 저자들은 제한성 병기와 확장성 병기 소세포폐암 환자에서 irinotecan 과 cisplatin 을 1차 약제로 투여시 효과 및 부작용을 조사하였다. 방 법 : 2002 년 1월부터 2004 년 12월까지 조직학적으로 진단된 소세포폐암 환자를 대상으로 $60mg/m^2$ 의 irinotecan 을 1주 간격으로 세 번, $60mg/m^2$ 의 cisplatin 을 첫날 투여하였다. 제한성 병기 환자에게 흉곽에 대한 방사선 치료를 초기에 병합하였고 당시 irinotecan 의 용량은 $40mg/m^2$으로 줄였다. 완전관해가 확인 된 경우에는 예방적 뇌 방사선 조사를 하였다. 결 과 : 제한성 병기 환자 20명의 중앙 생존기간은 20개월, 반응율은 85%, 중앙 무진행 생존기간은 12.0 개월이었다. 확장성병기 환자 18 명의 중앙 생존기간은 14.5개월, 반응율은 83.4%, 중앙 무진행 생존기간은 6.3개월이었다. 주요 부작용은 혈액학적 이상과 위장관 이상이었으나 부작용으로 사망한 경우는 없었다. 결 론 : Irinotecan 과 cisplatin 병합요법은 제한성 병기 및 확장성 병기 소세포폐암 환자의 1차 치료제로 효과적이었고 심각한 부작용은 없었다.

References

  1. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-33 https://doi.org/10.1016/S1040-8428(03)00118-5
  2. Chua YJ, Steer C, Yip D. Recent advances in management of small-cell lung cancer. Cancer Treat Rev 2004;30:521-43 https://doi.org/10.1016/j.ctrv.2004.06.003
  3. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998;16:1068-74 https://doi.org/10.1200/JCO.1998.16.3.1068
  4. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91 https://doi.org/10.1056/NEJMoa003034
  5. World Health Organization. WHO Handbook for Results of Cancer Treatment: WHO offset Publication No. 48. Geneva, Switzerland, Word Health Organization, 1979
  6. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama T, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7 https://doi.org/10.1093/oxfordjournals.jjco.a039642
  7. Oka M, Fukuda M, Kuba M, Ichiki M, Rikimaru T, Soda H, et al. Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 2002;38:1998-2004 https://doi.org/10.1016/S0959-8049(02)00191-0
  8. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4785-93
  9. Stuschke M, Pottgen C. Localized small-cell lung cancer: which type of thoracic radiotherapy and which time schedule. Lung Cancer 2004;45:133-7 https://doi.org/10.1016/S0169-5002(04)00243-0
  10. Mitsuoka S, Kudoh S, Takada Y. Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG 9902, Proc Am Soc Clin Oncol. 2004;23:624a
  11. Han JY, Cho KH, Lee DH, Kim HY, Kim EA, Lee SY, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol. 2005;23:3488-94 https://doi.org/10.1200/JCO.2005.01.082